PHARMAMAR HA OPTADO POR LA RETIRADA DE LA SOLICITUD DE AUTORIZACIÓN DE COMERCIALIZACIÓN DE APLIDIN ( PLITIDEPSIN ) ... WITHDRAWAL OF APPLICATIÓN FOR THE MARKETING AUTHORISATION OF APLIDIN ( PLITIDEPSIN ) JULY 23 , 2025 .
26 abril 2024
ASCO 2024 . SERPLULIMAB vs. Placebo Combined With Chemotherapy as First-Line Treatment For EXTENSIVE-STAGE Small Cell Lung Cancer : Extended Follow-Up Results And Patient-Reported Outcomes From The International PHASE III ASTRUM-005 Study .